Juan Camilo Arjona Ferreira
Technik-/Wissenschafts-/F&E-Leiter bei ORGANON & CO.
Vermögen: 239 $ am 30.04.2024
Profil
Juan Camilo Arjona Ferreira is currently the Chief Medical Officer & Head of R&D at Organon & Co. Prior to his current position, he held the role of Chief Medical Officer at Myovant Sciences Ltd.
from 2017 to 2023.
Before that, he served as the Senior Vice President of Clinical Development at Shionogi, Inc. from 2014 to 2017.
From 2002 to 2014, he worked as the Executive Director of Clinical Research at Merck & Co., Inc. Dr. Arjona Ferreira obtained his graduate degree from Universidad del Rosario in 1993.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
ORGANON & CO.
0,00% | 29.03.2024 | 13 ( 0,00% ) | 239 $ | 30.04.2024 |
Aktive Positionen von Juan Camilo Arjona Ferreira
Unternehmen | Position | Beginn |
---|---|---|
ORGANON & CO. | Technik-/Wissenschafts-/F&E-Leiter | 05.09.2023 |
Ehemalige bekannte Positionen von Juan Camilo Arjona Ferreira
Unternehmen | Position | Ende |
---|---|---|
MYOVANT SCIENCES LTD. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2023 |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2017 |
MERCK & CO., INC. | Corporate Officer/Principal | 01.03.2014 |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ausbildung von Juan Camilo Arjona Ferreira
Universidad del Rosario | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
ORGANON & CO. | Health Technology |
Private Unternehmen | 3 |
---|---|
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |